After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens in hopes of reaching a broader patient population. And AstraZeneca, utilizing a ...
On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...
GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...
A Reuters report regarding the rejection of Unilever's $68 billion offer for GlaxoSmithKline’s consumer healthcare assets is raising questions, including whether Unilever should raise the bid and risk ...
GSK has outperformed both the healthcare sector and S&P 500 this year, which is notable considering the spectre of high ...
(Reuters) – Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline’s consumer healthcare assets was rejected — should it raise the bid and risk overpaying or seek ...
Recent performance and why GSK stock is back on radar GSK (LSE:GSK) has quietly delivered a strong run this year, with the share price up about 34% year to date and roughly 44% over the past year, ...
TipRanks on MSN
GSK price target raised to 1,500 GBp from 1,200 GBp at HSBC
HSBC analyst Rajesh Kumar raised the firm’s price target on GSK (GSK) to 1,500 GBp from 1,200 GBp and keeps a Reduce rating on the shares as part ...
Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK. GSK on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback